Kiora Pharmaceuticals IncKPRX

Kiora Pharmaceuticals’ most concrete recent milestone is a Phase 2 authorisation for its photoswitch drug KIO-301 in advanced retinitis pigmentosa, granted in mid-2025, but that is a regulatory step, not a revenue one. The company’s 10-Q for the quarter ended March 31, 2026 shows a net loss of $2.4 million, operating loss of $2.5 million, and zero product revenue. Cash and cash equivalents stood at $11.0 million on March 31, 2026, while short-term investments added another $2.9 million. Net cash used in operating activities was $3.2 million over the quarter, and research and development expense was $2.1 million.

Kiora’s pipeline includes KIO-301 and KIO-104, with both having secured orphan-drug designations in the US (KIO-301 in March 2022) and the EU (KIO-301 in July 2024; KIO-104 in May 2015). The company’s media rails feature patient stories and product imagery, but the filings make clear that no revenue has yet flowed from these programmes. The latest Kiora 10-Q lists total assets of $21.2 million against liabilities of $7.3 million, giving shareholders’ equity of $13.9 million. Diluted loss per share was $0.58 on 4.2 million diluted shares.

The June 12, 2026 Form 4s show several insiders buying or selling small blocks of shares, while the June 18, 2026 8-K reports no material new contracts, financings or product launches. The company’s pipeline science page and clinical trials page confirm ongoing studies, but provide no revenue or sales forecasts. The evidence points to a pre-revenue biotech still funding its science from a $13.9 million equity base.

For readers used to polished biotech platforms, Kiora’s filing reality is sobering: cash burn, zero revenue, and a pipeline that has cleared regulatory hurdles without yet clearing the cash-register one. The images on Kiora’s media pages-inspirational patient stories and product graphics-are real content, but they do not constitute revenue or earnings. The company’s official investor-relations page offers email alerts, but the filings do not provide forward-looking statements or guidance.

There is no chart context in the supplied evidence set. The stock trades on the OTC market; liquidity and volume details are not supplied by the evidence and therefore cannot be asserted.

Kiora Pharmaceuticals remains a clinical-stage company whose value depends on the eventual success of KIO-301 and KIO-104 in regulated trials and, ultimately, in the market. Until product revenue or a clear commercial pathway is disclosed, the balance sheet will continue to reflect the costs of science rather than the receipts of sales.